POSSIBILITY OF DIAGNOSING ESSENTIAL TROMBOCYTHEMIA AT THE STAGE OF PRIMARY MEDICAL CARE



Cite item

Full Text

Abstract

Presents a clinical case of essential thrombocythemia (ET) in a 39-year-old woman with a description of the epidemiology, clinical and diagnostic criteria, patient management tactics, as well as a discussion of probable complications and prognosis for ET. The need for careful outpatient monitoring with assessment of the clinical picture, dynamics of blood counts, bone marrow trepanobiopsy and molecular genetic research to determine mutations of the MPL and CALR genes is emphasized. It was concluded that there are gaps in medical examination, the implementation of which would undoubtedly contribute to the early detection of ET and the implementation of pathogenetic therapy with antiplatelet agents to prevent complications.

Full Text

Restricted Access

About the authors

Vitaly Gorban

Kuban State Medical University, Krasnodar, Russia

Author for correspondence.
Email: gorbanvv@mail.ru
ORCID iD: 0000-0001-8665-6796

Dr. Sci. (Med.), Head of the Department of Polyclinic Therapy with Course of General Medical Practice (Family Medicine) of the Faculty of Advanced Training and Professional Retraining of Specialists
Russian Federation, Kuban State Medical University; 4, Mitrofan Sedin St., Krasnodar, 3500063, Russia

Valeria Manto

ФГБУ ВО Кубанский Государственный медицинский университет МЗ РФ

Email: lera.menshikh@mail.ru
ORCID iD: 0000-0001-5601-6034

Postgraduate of the Department of Polyclinic Therapy with Course of General Medical Practice (Family Medicine) of the Faculty of Advanced Training and Professional Retraining of Specialists
Russian Federation, Mitrofan Sedin St., Krasnodar, 3500063, Russia

Nikita Bergen

Kuban State Medical University, Krasnodar, Russia

Email: Fredibergsn23@mail.ru
ORCID iD: 0009-0000-0676-0367

5th year student, Faculty of Medicine, Kuban State Medical University
Russian Federation, 4, Mitrofan Sedin St., Krasnodar, 3500063, Russia

Kamila Arzumanyan

Kuban State Medical University, Krasnodar, Russia

Email: arzumanyan.kamilla@mail.ru
ORCID iD: 0000-0001-8739-6340

6th year student, Faculty of Medicine, Kuban State Medical University; 4
Russian Federation, 4, Mitrofan Sedin St., Krasnodar, 3500063, Russia

References

  1. Yu Y., Zhang X., Shi Q. et al. Essential thrombocytosis with recurrent spontaneous abortion in the mid trimester: A case report. Medicine (Baltimore). 2019; 98(26):e16203. doi: 10.1097/MD.0000000000016203
  2. Vainchenker W., Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017; 129(6):667-679. doi: 10.1182/blood-2016-10-695940
  3. Melikjan A.L., Subortseva I.N., Sudarikov A.B. et al. Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease. Therapeutic Archive. 2017;89(7):4 9. (In Russ.)
  4. doi: 10.17116/terarkh20178974-9
  5. Padmanabhan A., Connelly-Smith L., Aqui N. et all. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34(3):171-354. doi: 10.1002/jca.21705
  6. Melikyan A.L., Kovrigina A.M., Subortseva I.N. et all. National сlinical recommendations for diagnosis and therapy of ph-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition 2018). Russian journal of hematology and transfusiology. 2018;63(3):275-315. (In Russ.)
  7. Tefferi A., Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599-1613. doi: 10.1002/ajh.26008
  8. Mora B., Passamonti F. Developments in diagnosis and treatment of essential thrombocythemia. Expert Review of Hematology. 2019;12(3):159-171. doi: 10.1080/17474086.2019.1585239
  9. Accurso V., Santoro M., Mancuso S. et al. The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep. Clinical Medicine Insights: Blood Disorders. 2020;13. doi: 10.1177/2634853520978210
  10. İskender D., Yılmaz-Ergani S., Aksoy M., et all. High Rate of Obstetric Complications in Patients With Essential Thrombocythemia. Cureus. 2021;13 (12):e20449. doi: 10.7759/cureus.20449
  11. Kwiatkowski J., Kuliszkiewicz-Janus M., Potoczek S. et al. What factors determine the pregnancy outcome in patients with essential thrombocythemia? J Matern Fetal Neonatal Med. 2022;35(24):4734-4738. doi: 10.1080/14767058.2020.1863362
  12. Cattaneo D., Croci G.A., Bucelli C. et al. Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study. Front Oncol. 2021;12(11):637116. doi: 10.3389/fonc.2021.637116
  13. Tefferi A., Guglielmelli P., Larson D.R. et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507-13. doi: 10.1182/blood-2014-05-579136
  14. Arber D.A., Orazi A., Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. doi: 10.1182/blood-2016-03-643544
  15. Wang Y., Ran F., Lin J. et al. Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL. Technol Cancer Res Treat. 2023; 22. doi: 10.1177/15330338231154092
  16. Mroczkowska-Bękarciak A., Wróbel T. BCR: ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing. Front Genet. 2023;14:1241912. doi: 10.3389/fgene.2023.1241912
  17. Okazaki H., Doi T., Izumikawa M. et al. Pulsatile tinnitus as a first symptom of essential thrombocythemia. Am J Otolaryngol. 2011;32(3):263-4. doi: 10.1016/j.amjoto.2010.03.004
  18. Michiels J.J., Berneman Z., Schroyens W. et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets. 2006;17(8):528-44. doi: 10.1080/09537100600758677
  19. Inoue S., Okiyama N., Okune M. et al. Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works. J Dermatol. 2017;44(1):84-87. doi: 10.1111/1346-8138.13561
  20. Robinson A.J., Godfrey A.L. Low-Risk Essential Thrombocythemia: A Comprehensive Review. Hemasphere. 2021;5(2):e521. doi: 10.1097/HS9.0000000000000521
  21. Zulkeflee R.H., Zulkafli Z., Johan M.F. et al. Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN). Int J Environ Res Public Health. 2021;18(14):7582. doi: 10.3390/ijerph18147582
  22. Gaman A. M. et al. Crosstalk between oxidative stress, chronic inflammation and disease progression in essential thrombocythemia. Rev Chim. 2019;70(10):3486-3489. doi: 10.37358/RC.19.10.7581
  23. Carobbio A., Ferrari A., Masciulli A., et al. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019;3(11):1729-1737. doi: 10.1182/bloodadvances.2019000211.
  24. Awada H., Voso M.T., Guglielmelli P. et all. Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding. Cancers (Basel). 2020;12(7):1746. doi: 10.3390/cancers12071746
  25. Abu-Tineh M., Yassin M.A. Extreme Levels of Platelet Count in Essential Thrombocythemia: Management and Outcome, Report of Two Cases. Case Rep Oncol. 2020;13(2):606-610. doi: 10.1159/000507363
  26. Beer P.A., Erber W.N., Campbell P.J. et al. How I treat essential thrombocythemia. Blood. 2011;117(5):1472-82. doi: 10.1182/blood-2010-08-270033
  27. Sakamoto Y., Nito C., Abe A. et al. Aspirin, but not clopidogrel, ameliorates vasomotor symptoms due to essential thrombocythemia: A case report. J Neurol Sci. 2016;15(365):74-5. doi: 10.1016/j.jns.2016.04.014

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 70763 от 21.08.2017 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies